

Do You Have Recurrent or Metastatic Breast Cancer?



If you are living with Estrogen Receptor positive (ER+) metastatic breast cancer (MBC) or have had an ER+ recurrence, your scan may be holding key information to help you and your doctor make a more informed decision about your treatment plan.

SCANS

What Information Does A Positron Emission Tomography (PET) Scan Provide?

An FDG-PET scan provides detailed images of your metabolic body function and uses a radioactive drug (also known as a tracer or imaging agent) to show metabolically active lesions. But what if there were a way to find out even more precise information that is specific to you?



CERIANNA™ (FLUOROESTRADIOL F-18; FES)

What Is It & How Is It Administered?

Cerianna is the first imaging tracer indicated for the detection of ER+ lesions in people with recurrent breast cancer or who are living with MBC. The PET scan begins about one hour after Cerianna is injected into a vein in the arm. Cerianna may be used in addition to biopsy.



If you are considering or have started treatment with SERMs or SERDs (Tamoxifen or Fulvestrant, respectively) then discussion with your physician in regards to the potential timing of Cerianna is encouraged. Common side effects include pain at the injection-site and temporary altered taste sensation.



POTENTIAL BENEFITS OF CERIANNA*

- Detect ER+ lesions when considering endocrine therapy for patients at initial diagnosis with MBC or after progression of metastatic disease.
- Assess ER status of lesions that are difficult or dangerous to biopsy, when other imaging tests are uncertain or suspicious. or biopsy is non-diagnostic

**Clinical use cases have been independently validated by an expert panel of leading healthcare oncology providers and researchers.*

CERIANNA™ PET



A DIFFERENT TYPE OF SCAN. A DIFFERENT APPROACH TO YOUR TREATMENT PLAN.



ADVOCATE

Knowledge is Power

Cerianna has the ability to inform your doctor of the ER+ receptor status of your metastatic or recurrent tumors — essentially creating a “whole-body” picture of ER+ lesions.



Knowing if your lesions are ER+ may allow your oncologist to more precisely determine the most appropriate course of treatment.



Ask your doctor if Cerianna is right for you!

IMPORTANT CONSUMER SAFETY INFORMATION

CERIANNA (fluoroestradiol F18) injection is a diagnostic imaging agent (sometimes called a radiopharmaceutical or tracer). CERIANNA is used with Positron Emission Tomography (PET) imaging to detect a specific protein called the estrogen receptor on breast cancer tumors that have recurred or spread from their original site. CERIANNA is used as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.

Contraindications: None

Adverse Reactions: The most common side effects seen with CERIANNA were pain at the site of injection and temporary altered taste sensation.

To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp, a GE Healthcare Company at +1.800.654.0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

For full Prescribing Information click on or visit www.gehealthcare.com/cerianna-pi